Eye Gate Pharma
Pharmaceuticals, 271 Waverley Oaks Rd, Waltham, , 2452, Massachusetts, United States, 11-50 Employees
Phone Number: +17*********
Who is EYEGATE PHARMA
We are a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. EGP-437, our first prod...
Read More
-
Headquarters: 271 Waverley Oaks Rd, Waltham, Massachusetts, 2452, United States
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from EYEGATE PHARMA
EyeGate Pharma Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding EyeGate Pharma
Answer: EyeGate Pharma's headquarters are located at 271 Waverley Oaks Rd, Waltham, , 2452, Massachusetts, United States
Answer: EyeGate Pharma's phone number is +17*********
Answer: EyeGate Pharma's official website is https://eyegatepharma.com
Answer: EyeGate Pharma's revenue is $10 Million to $25 Million
Answer: EyeGate Pharma's SIC: 2834
Answer: EyeGate Pharma's NAICS: 325412
Answer: EyeGate Pharma has 11-50 employees
Answer: EyeGate Pharma is in Pharmaceuticals
Answer: EyeGate Pharma contact info: Phone number: +17********* Website: https://eyegatepharma.com
Answer: We are a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. EGP-437, our first product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through our proprietary innovative drug delivery system, the EyeGate® II Delivery System. EGP-437 is being developed under the 505(b)(2) New Drug Application, or NDA, regulatory pathway for drugs submitted for approval to the U.S. Food and Drug Administration, or FDA, which enables an applicant to rely, in part, on the FDA’s findings of safety and efficacy for an existing product, or published literature, in support of its NDA. In addition, through our acquisition of Jade in March 2016 (the “Jade Acquisition”), we are developing products using cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing properties when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. Our first CMHA-S-based product, the EyeGate Ocular Bandage Gel (“OBG”), is a topically-applied eye drop formulation that is being developed under the 510(k) De Novo path for devices submitted for marketing clearance to the U.S. FDA.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month